Lowy: NCI to focus on multi-cancer detection tests, diversity in workforce, clinical trials

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.

April 10, 2026

Vol.52 No.14

By Claire Marie Porter and Paul Goldberg

Podcast The Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst and Paul Goldberg

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus.

March 06, 2026

Vol.52 No.09

Lowy: NCI to focus on multi-cancer detection tests, diversity in workforce, clinical trials

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Renew today!

Subscriber content

Never miss an issue!

Login

Lowy: NCI to focus on multi-cancer detection tests, diversity in workforce, clinical trials

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdyNCI expects record-breaking spending on extramural research

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

Never miss an issue!

Login

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”